<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40511773</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1073</EndPage><MedlinePgn>1062-1073</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003833</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal venous thromboembolism chemoprophylaxis strategy after surgery for IBD is not defined.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the real-world efficacy of chemoprophylaxis strategies after surgery for IBD in a retrospective cohort.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of medical records from the National Surgical Quality Improvement Program IBD Collaborative of patients treated between July 2020 to October 2023.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Seventeen medical centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with IBD undergoing colectomy and/or proctectomy were included.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Chemoprophylaxis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Thirty-day venous thromboembolism (clot) rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During 3 years, 1797 patients were eligible for chemoprophylaxis and included in the analysis, of whom 44 (2.4%) developed a clot within 30 days: 50% before and after discharge, respectively. Clots were diagnosed a median of 9 days postoperatively. The most common clots were portomesenteric (39%), pulmonary embolism (27%), and upper extremity (18%). Before discharge, clot rates differed by chemoprophylaxis strategy: enoxaparin (0.57%) versus unfractionated heparin (2.1%, p = 0.006). Any extended chemoprophylaxis was used in 50.5%, and clot rates differed by strategy: no extended chemoprophylaxis (1.4%), enoxaparin (0.63%), and others (3.5%, p = 0.01). Chemoprophylaxis strategies were not associated with bleeding complications. Multivariable analysis revealed that preoperative systemic inflammatory response syndrome ( p = 0.0005) and extended resections ( p &lt; 0.0001) were independent risk factors for postoperative clots. Patients with 0, 1, or 2 risk factors had clot rates of 1.2%, 4.0%, and 13.5%, respectively ( p &lt; 0.0001). Inpatient and extended prophylaxis with enoxaparin were independently associated with a lower risk of clots both before and after discharge ( p = 0.002 and p = 0.02, respectively), with relative risk reductions of 74.8% and 72.6%. For a clot rate of 2.5%, the estimated number needed to treat with enoxaparin in-hospital and postdischarge was 54 and 55 patients, respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The limitations to this study were generalizability and selection bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After IBD surgery, venous thromboembolism chemoprophylaxis with enoxaparin was associated with a decreased risk of clot formation before and after discharge. Patients at highest risk may benefit the most from extended chemoprophylaxis. See Video Abstract .</AbstractText><AbstractText Label="PATRONES DE PRCTICA, RESULTADOS Y ESTRATIFICACIN DEL RIESGO EN LA PROFILAXIS DE LA TROMBOEMBOLIA VENOSA TRAS CIRUGA POR ENFERMEDAD INFLAMATORIA INTESTINAL ESTUDIO COLABORATIVO DEL PROGRAMA NACIONAL DE MEJORA DE LA CALIDAD QUIRRGICA SOBRE EII" NlmCategory="UNASSIGNED">ANTECEDENTES:No se ha definido la estrategia &#xf3;ptima de quimioprofilaxis de la tromboembolia venosa tras la cirug&#xed;a por enfermedad inflamatoria intestinal.OBJETIVO:Investigar la eficacia real de las estrategias de quimioprofilaxis tras la cirug&#xed;a por enfermedad inflamatoria intestinal en una cohorte retrospectiva.DISE&#xd1;O:Entre julio de 2020 y octubre de 2023, la Colaboraci&#xf3;n sobre Enfermedad Inflamatoria Intestina deel Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica.ENTORNO:Diecisiete centros m&#xe9;dicos.PACIENTES:Pacientes con enfermedad inflamatoria intestinal sometidos a colectom&#xed;a y/o proctectom&#xed;a.INTERVENCIONES:Quimioprofilaxis.PRINCIPALES MEDIDAS DE RESULTADO:Tasas de tromboembolia venosa (co&#xe1;gulos) a 30 d&#xed;as.RESULTADOS:Durante tres a&#xf1;os, 1797 pacientes fueron elegibles para quimioprofilaxis y fueron analizados, de los cuales 44 (2.4 %) desarrollaron un co&#xe1;gulo en un plazo de 30 d&#xed;as: el 50 % antes y despu&#xe9;s del alta, respectivamente. Los co&#xe1;gulos se diagnosticaron una mediana de 9 d&#xed;as despu&#xe9;s de la operaci&#xf3;n. Los co&#xe1;gulos m&#xe1;s frecuentes fueron portomesent&#xe9;ricos (39 %), embolia pulmonar (27 %) y extremidades superiores (18 %). Antes del alta, las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia de quimioprofilaxis: enoxaparina (0.57 %) frente a heparina no fraccionada (2.1 %), p = 0.006. Se utiliz&#xf3; una quimioprofilaxis prolongada en el 50.5 % de los casos y las tasas de co&#xe1;gulos difirieron seg&#xfa;n la estrategia: sin quimioprofilaxis prolongada (1.4 %), enoxaparina (0.63 %) y otras (3.5 %) p = 0.01. Las estrategias de quimioprofilaxis no se asociaron con complicaciones hemorr&#xe1;gicas. El an&#xe1;lisis multivariable revel&#xf3; que el s&#xed;ndrome de respuesta inflamatoria sist&#xe9;mica preoperatoria ( p = 0.0005) y las resecciones extendidas ( p &lt; 0.0001) eran factores de riesgo independientes para los co&#xe1;gulos postoperatorios. Los pacientes con 0, 1 o 2 factores de riesgo tuvieron tasas de co&#xe1;gulos del 1.2 %, 4.0 % y 13.5 %, respectivamente ( p &lt; 0.0001). La profilaxis hospitalaria y prolongada con enoxaparina se asoci&#xf3; de forma independiente con un menor riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta ( p = 0.002 y p = 0.02, respectivamente), con reducciones del riesgo relativo del 74.8 % y el 72.6 %. Para una tasa de co&#xe1;gulos del 2.5 %, el n&#xfa;mero estimado de pacientes que deb&#xed;an recibir tratamiento con enoxaparina durante la hospitalizaci&#xf3;n y despu&#xe9;s del alta fue de 54 y 55, respectivamente.LIMITACIONES:Generalizaci&#xf3;n; sesgo de selecci&#xf3;n.CONCLUSIONES:Tras la cirug&#xed;a por enfermedad inflamatoria intestinal, la quimioprofilaxis de la tromboembolia venosa con enoxaparina se asoci&#xf3; con una disminuci&#xf3;n del riesgo de co&#xe1;gulos antes y despu&#xe9;s del alta. Los pacientes con mayor riesgo pueden beneficiarse m&#xe1;s de una quimioprofilaxis prolongada. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-2549-9042</Identifier><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2646-0625</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of California, San Diego School of Medicine, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0003-3418-6774</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Massachusetts General Hospital, Colorectal Surgery Program, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen T</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-9138-186</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla F</ForeName><Initials>CF</Initials><Identifier Source="ORCID">0000-0002-9526-0643</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Cincinnati, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0382-880</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-8273-9471</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Stanford Health Care, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krane</LastName><ForeName>Mukta K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-4872-1061</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Washington Medical Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5814-3915</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-2014-0302</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-4010-5275</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Penn State Health, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mount Sinai Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NSQIP IBD Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemoprophylaxis</Keyword><Keyword MajorTopicYN="N">Colectomy</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Direct oral anticoagulants</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ileoanal pouch</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Proctectomy</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Anzlovar</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batten</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belding-Schmitt</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohne</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowell</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davids</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Leon</LastName><ForeName>Elmer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devaney</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Divino</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Austin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germaine</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyette</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilbert</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirbe</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggins</LastName><ForeName>Pam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyke</LastName><ForeName>Roxanne</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Justiniano</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenan</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaitov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunitake</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavryk</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messaris</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Reba</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mutch</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narsule</LastName><ForeName>Chaitan</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paquette</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plietz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poylin</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prachand</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramamoorthy</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Rocco</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenkranz</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansone</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Radhika</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spain</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinhagen</LastName><ForeName>Randolph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strong</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylla</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Anila</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Valora</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomaska</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torbela</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valerian</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whyte</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40511773</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003833</ArticleId><ArticleId IdType="pii">00003453-990000000-00977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brady MT, Patts GJ, Rosen A, et al. Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60:61&#x2013;67.</Citation></Reference><Reference><Citation>GamalEldin M, DeHaan RK, Sklow B, et al. Portomesenteric venous thrombosis after colorectal surgery for inflammatory bowel disease: a call to action? [ASCRS abstract POD232]. Dis Colon Rectum. 2021;64:e109&#x2013;e364.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Cima RR, Habermann EB. Timing and location of venous thromboembolisms after surgery for inflammatory bowel disease. J Surg Res. 2024;296:563&#x2013;570.</Citation></Reference><Reference><Citation>Wallaert JB, De Martino RR, Marsicovetere PS, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum. 2012;55:1138&#x2013;1144.</Citation></Reference><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, et al.; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975&#x2013;980.</Citation></Reference><Reference><Citation>Fleming F, Gaertner W, Ternent CA, et al. The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery. Dis Colon Rectum. 2018;61:14&#x2013;20.</Citation></Reference><Reference><Citation>Eisenstein S, Holubar SD, Hilbert N, et al. The ACS National Surgical Quality Improvement Program-Inflammatory Bowel Disease Collaborative: design, implementation, and validation of a disease-specific module. Inflamm Bowel Dis. 2019;25:1731&#x2013;1739.</Citation></Reference><Reference><Citation>Greaves SW, Holubar SD. Preoperative hospitalization is independently associated with increased risk for venous thromboembolism in patients undergoing colorectal surgery: a national surgical quality improvement program database study. Dis Colon Rectum. 2015;58:782&#x2013;791.</Citation></Reference><Reference><Citation>McKenna NP, Bews KA, Behm KT, Mathis KL, Lightner AL, Habermann EB. Do patients with inflammatory bowel disease have a higher postoperative risk of venous thromboembolism or do they undergo more high-risk operations? Ann Surg. 2020;271:325&#x2013;331.</Citation></Reference><Reference><Citation>Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(suppl 3):304&#x2013;312.</Citation></Reference><Reference><Citation>Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632&#x2013;634.</Citation></Reference><Reference><Citation>Benlice C, Holubar SD, Gorgun E, et al. Extended venous thromboembolism prophylaxis after elective surgery for IBD patients: nomogram-based risk assessment and prediction from nationwide cohort. Dis Colon Rectum. 2018;61:1170&#x2013;1179.</Citation></Reference><Reference><Citation>Cheong JY, Connelly TM, Russell T, et al. Venous thromboembolism risk stratification for patients undergoing surgery for IBD using a novel six factor scoring system using NSQIP-IBD registry. ANZ J Surg. 2023;93:1620&#x2013;1625.</Citation></Reference><Reference><Citation>Cordell WH. Number needed to treat (NNT). Ann Emerg Med. 1999;33:433&#x2013;436.</Citation></Reference><Reference><Citation>Montero Ruiz E, Baldominos Utrilla G, L&#xf3;pez &#xc1;lvarez J, Santolaya Perrin R. Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients. Thromb Res. 2011;128:440&#x2013;445.</Citation></Reference><Reference><Citation>Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422&#x2013;1430.</Citation></Reference><Reference><Citation>Lee CHA, Jia X, Lipman JM, et al. Defining the economic burden of perioperative venous thromboembolism in inflammatory bowel disease in the United States. Dis Colon Rectum. 2021;64:871&#x2013;880.</Citation></Reference><Reference><Citation>Leeds IL, DiBrito SR, Canner JK, Haut ER, Safar B. Cost-benefit limitations of extended, outpatient venous thromboembolism prophylaxis following surgery for Crohn&#x2019;s disease. Dis Colon Rectum. 2019;62:1371&#x2013;1380.</Citation></Reference><Reference><Citation>Leeds IL, Haut ER. Are we really supposed to start giving venous thromboembolism prophylaxis for a month after outpatient surgery? JAMA Surg. 2019;154:1133.</Citation></Reference><Reference><Citation>Prien C, Ribakow D, Steele SR, et al. What about patient cost? Defining copay and out-of-pocket costs of extended venous thromboembolism chemoprophylaxis after colorectal surgery. J Gastrointest Surg. 2023;27:152&#x2013;154.</Citation></Reference><Reference><Citation>Stewart KT, Jafari H, Pattillo J, et al. Avoiding the needle: a quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery. Gynecol Oncol. 2024;188:131&#x2013;139.</Citation></Reference><Reference><Citation>Ogilvie JW Jr, Khan MT, Hayakawa E, Parker J, Luchtefeld MA. Low-dose rivaroxaban as extended prophylaxis reduces postdischarge venous thromboembolism in patients with malignancy and IBD. Dis Colon Rectum. 2024;67:457&#x2013;465.</Citation></Reference><Reference><Citation>Holubar SD, Eisenstein S, Bordeianou L, et al. Venous thromboembolism prophylaxis practice patterns, outcomes, and risk stratification after surgery for inflammatory bowel disease: a NSQIP IBD Collaborative study. Dis Colon Rectum. 2025;68:e228&#x2013;e229.</Citation></Reference><Reference><Citation>Cordova-Cassia C, Wong D, Cotter MB, Cataldo TE, Poylin VY. Patient&#x2019;s compliance is a contributor to failure of extended antithrombotic prophylaxis in colorectal surgery: prospective cohort study. Surg Endosc. 2022;36:267&#x2013;273.</Citation></Reference><Reference><Citation>Elzaafarany A, Tawfik A, Igbekele T, Day A. EP-351 Extended VTE prophylaxis in patients undergoing elective surgery for colorectal cancer in a district general hospital and its compliance with NICE guidelines. Br J Surg. 2022;109(Suppl 5):znac245.091.</Citation></Reference><Reference><Citation>Yeung T, Ng S, Sidhu R, Ali M. 463 Adherence to extended venous thromboembolism prophylaxis for post operative resection of colorectal malignancies. Br J Surg. 2023;110(Suppl 7):znad258.105.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36842685</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2341-1929</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Revista espanola de anestesiologia y reanimacion</Title><ISOAbbreviation>Rev Esp Anestesiol Reanim (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>139</EndPage><MedlinePgn>129-139</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redare.2023.02.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2341-1929(23)00049-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION">COVID-19 induces coagulopathy associated with an increase of thromboembolic events. Due to the lack of agreement on recommendations for thromboprophylactic management, the aim of this study was to study the dosages of LMWH used in critically ill COVID-19 patients assessing the effect on their outcome.</AbstractText><AbstractText Label="METHODS">We evaluated data of the Reg-COVID19. According to LMWH dose two groups were analyzed: prophylaxis and treatment. Primary outcome was the relationship of LMWH dosage with mortality. Secondary outcomes included the incidence of thrombotic and bleeding events, length of ICU stay, invasive mechanical ventilation, and thrombotic and inflammatory parameters.</AbstractText><AbstractText Label="RESULTS">Data of 720 patients were analyzed, 258 in the prophylaxis group and 462 in the treatment group. C Reactive Protein, invasive mechanical ventilation, tocilizumab and corticosteroid treatments were related with the choice of LMWH dose. Hemorrhagic events (66/720, 9.2%) and thrombotic complications (69/720, 9.6%) were similar in both groups (p&#x202f;=&#x202f;.819 and p&#x202f;=&#x202f;.265), as was the time course of the thrombotic events, earlier than hemorrhagic ones (9 [3-18] and 12 [6-19] days respectively). Mortality was lower in prophylaxis group (25.2% versus 35.1%), but once an inverse probability weighting model was applied, we found no effect of LMWH dose.</AbstractText><AbstractText Label="CONCLUSION">We found no benefit or harm with the administration of therapeutic or prophylactic LMWH dose in COVID19 critically ill patients. With a similar rate of hemorrhagic or thrombotic events, the LMWH dose had no influence on mortality. More studies are needed to determine the optimal thromboprophylaxis protocol for critically ill patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sociedad Espa&#xf1;ola de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferrandis</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitari i Polit&#xe8;cnic La Fe, Valencia, Spain. Electronic address: raquelferrandis@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escontrela</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitario Infanta Leonor, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrando</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Cl&#xed;nic, Institut d'Investigacions Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Espa&#xf1;a, CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Cl&#xed;nica Universidad de Navarra, Pamplona, Navarra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Librero</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Navarrabiomed, Complejo Hospitalario de Navarra-Universidad P&#xfa;blica de Navarra, IDISNA, Pamplona, Navarra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llau</LastName><ForeName>J V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitario Doctor Peset, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jefe de Servicio de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitario Cruces, Barakaldo, Vizcaya, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajares</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitari i Polit&#xe8;cnic La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapia</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arruti</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Innovation and Technology Area, Ubikare SL, Getxo, Vizcaya, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassas</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Mois&#xe8;s Broggi, Sant Joan Desp&#xed;, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Cl&#xed;nic, Institut d'Investigacions Biom&#xe8;dica Agust Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Anestesiolog&#xed;a y Cuidados Cr&#xed;ticos, Hospital Cl&#xed;nic, Institut d'Investigacions Biom&#xe8;dica Agust Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 Spanish ICU Network Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Anestesiol Reanim (Engl Ed)</MedlineTA><NlmUniqueID>101778594</NlmUniqueID><ISSNLinking>2341-1929</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N">Los pacientes COVID-19 presentan una coagulopat&#xed;a caracterizada por una elevada incidencia de complicaciones tromboemb&#xf3;licas. Ante la controversia existente sobre el manejo de la tromboprofilaxis, se llev&#xf3; a cabo un estudio con el objetivo de analizar el efecto de las diferentes dosis de heparina de bajo peso molecular (HBPM) utilizadas en los pacientes cr&#xed;ticos con COVID-19.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS">Se evaluaron datos del Reg-COVID19. Se compararon dos grupos de pacientes seg&#xfa;n la dosis de HBPM administrada: profilaxis y tratamiento. El objetivo primario fue determinar si hab&#xed;a relaci&#xf3;n de la dosis de HBPM con la mortalidad. Los objetivos secundarios incluyeron la incidencia de eventos tromb&#xf3;ticos y hemorr&#xe1;gicos, la duraci&#xf3;n de la estancia en UCI, la ventilaci&#xf3;n mec&#xe1;nica invasiva y par&#xe1;metros tromb&#xf3;ticos e inflamatorios.</AbstractText><AbstractText Label="RESULTADOS">Se analizaron datos de 720 pacientes, 258 en el grupo de profilaxis y 462 en el de tratamiento. La prote&#xed;na C reactiva, la ventilaci&#xf3;n mec&#xe1;nica invasiva, y el tratamiento con tocilizumab o corticosteroides se relacionaron con la elecci&#xf3;n de la dosis de HBPM. La incidencia de complicaciones hemorr&#xe1;gicas (66/720, 9.2%) y tromb&#xf3;ticas (69/720, 9.6%) fue similar en ambos grupos, al igual que el curso temporal de los eventos tromb&#xf3;ticos, que ocurrieron antes que los hemorr&#xe1;gicos (9 [3-18] y 12 [6-19] d&#xed;as respectivamente). La mortalidad fue menor en el grupo de profilaxis (25.2% frente a 35.1%), pero al aplicar un modelo de ponderaci&#xf3;n de probabilidad inversa, no se encontraron diferencias entre los grupos.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N">No se encontraron efectos beneficiosos ni perjudiciales relacionados con la administraci&#xf3;n de dosis profil&#xe1;cticas o terap&#xe9;uticas de HBPM en pacientes cr&#xed;ticos COVID-19, con una tasa similar de complicaciones hemorr&#xe1;gicas o tromb&#xf3;ticas. A partir de estos resultados, consideramos que son necesarios m&#xe1;s estudios para determinar el protocolo &#xf3;ptimo de tromboprofilaxis en estos pacientes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Sociedad Espa&#xf1;ola de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Complicaciones hemorr&#xe1;gicas</Keyword><Keyword MajorTopicYN="N">Complicaciones tromb&#xf3;ticas</Keyword><Keyword MajorTopicYN="N">Critically ill patients</Keyword><Keyword MajorTopicYN="N">Haemorrhagic complications</Keyword><Keyword MajorTopicYN="N">Heparina de bajo peso molecular</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Paciente cr&#xed;tico</Keyword><Keyword MajorTopicYN="N">Thromboprohylaxis</Keyword><Keyword MajorTopicYN="N">Thrombotic complications</Keyword><Keyword MajorTopicYN="N">Tromboprofilaxis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>19</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36842685</ArticleId><ArticleId IdType="pmc">PMC9957653</ArticleId><ArticleId IdType="doi">10.1016/j.redare.2023.02.004</ArticleId><ArticleId IdType="pii">S2341-1929(23)00049-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sriram K., Insel P.A. Inflammation and thrombosis in covid-19 pathophysiology: Proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev. 2021;101:545&#x2013;567. doi: 10.1152/physrev.00035.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00035.2020</ArticleId><ArticleId IdType="pmc">PMC8238137</ArticleId><ArticleId IdType="pubmed">33124941</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe1;ramo J.A. Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes. Reumatol Clin (Engl Ed.) 2020 Oct;15 doi: 10.1016/j.reuma.2020.06.004. S1699-258X(20)30143-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2020.06.004</ArticleId><ArticleId IdType="pmc">PMC7561343</ArticleId><ArticleId IdType="pubmed">35090606</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Yalavarthi S., Shi H., Gockman K., Zuo M., Madison J.A., et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11) doi: 10.1172/jci.insight.138999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark K., Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol [Internet] 2021;18:666&#x2013;682. doi: 10.1038/s41569-021-00552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00552-1</ArticleId><ArticleId IdType="pmc">PMC8100938</ArticleId><ArticleId IdType="pubmed">33958774</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja L.M., Wolf D., Zhao B., Akkanti B., McDonald M., Lelenwa L., et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;48 doi: 10.1016/j.carpath.2020.107233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carpath.2020.107233</ArticleId><ArticleId IdType="pmc">PMC7204762</ArticleId><ArticleId IdType="pubmed">32434133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann D., Sperhake J.P., L&#xfc;tgehetmann M., Steurer S., Edler C., Heinemann A., et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020;173:268&#x2013;277. doi: 10.7326/M20-2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-2003</ArticleId><ArticleId IdType="pmc">PMC7240772</ArticleId><ArticleId IdType="pubmed">32374815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo M., Bertinato E.M., Birocchi S., Brizio C., Malavolta D., Manzoni M., et al. Vol. 120. Georg Thieme Verlag; 2020. pp. 1230&#x2013;1232. (Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thrombosis and Haemostasis).</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1712097</ArticleId><ArticleId IdType="pmc">PMC7516356</ArticleId><ArticleId IdType="pubmed">32349132</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Disponible en: https://covid19treatmentguidelines.nih.gov/. NIH. 2020;2019:130.</Citation></Reference><Reference><Citation>Poterucha T.J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117:437&#x2013;444. doi: 10.1160/TH16-08-0620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH16-08-0620</ArticleId><ArticleId IdType="pubmed">27975101</ArticleId></ArticleIdList></Reference><Reference><Citation>Nougier C., Benoit R., Simon M., Desmurs-Clavel H., Marcotte G., Argaud L., et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020;18:2215&#x2013;2219. doi: 10.1111/jth.15016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15016</ArticleId><ArticleId IdType="pmc">PMC7405476</ArticleId><ArticleId IdType="pubmed">32668058</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi A., von Meijenfeldt F.A., Adelmeijer J., Calvo A., Iba&#xf1;ez C., Perdomo J., et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J Thromb Haemost. 2020;18:2646&#x2013;2653. doi: 10.1111/jth.15043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15043</ArticleId><ArticleId IdType="pmc">PMC7436627</ArticleId><ArticleId IdType="pubmed">32762118</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089&#x2013;1098. doi: 10.1007/s00134-020-06062-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06062-x</ArticleId><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavinio A., Ercole A., Battaglini D., Magnoni S., Badenes R., Taccone F.S., et al. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. Crit Care. 2021;25:1&#x2013;10. doi: 10.1186/s13054-021-03543-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03543-3</ArticleId><ArticleId IdType="pmc">PMC8061459</ArticleId><ArticleId IdType="pubmed">33888132</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour P., Talasaz A.H., Rashidi F., Sharif-Kashani B., Beigmohammadi M.T., Farrokhpour M., et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic. JAMA - J Am Med Assoc. 2021;325:1620&#x2013;1630. doi: 10.1001/jama.2021.4152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4152</ArticleId><ArticleId IdType="pmc">PMC7974835</ArticleId><ArticleId IdType="pubmed">33734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Meizlish M.L., Goshua G., Liu Y., Fine R., Amin K., Chang E., et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol. 2021;96:471&#x2013;479. doi: 10.1002/ajh.26102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26102</ArticleId><ArticleId IdType="pmc">PMC8013588</ArticleId><ArticleId IdType="pubmed">33476420</ArticleId></ArticleIdList></Reference><Reference><Citation>Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients. [Internet] [Accessed 15 May 2021]. NHLBI News Statement. Available in: https://www.nhlbi.nih.gov/news/2021/full-dose-bloodthinners-decreased-need-life-support-and-improved-outcome-hospitalized.</Citation></Reference><Reference><Citation>Ferrandis R., Llau J.V., Quintana M., Sierra P., Hidalgo F., Cassinello C., et al. COVID-19: Opening a new paradigm in thromboprophylaxis for critically ill patients? Crit Care. 2020;24:4&#x2013;6. doi: 10.1186/s13054-020-03052-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03052-9</ArticleId><ArticleId IdType="pmc">PMC7289223</ArticleId><ArticleId IdType="pubmed">32527286</ArticleId></ArticleIdList></Reference><Reference><Citation>Llau J.V., Ferrandis R., Sierra P., Hidalgo F., Cassinello C., G&#xf3;mez-Luque A., et al. SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients. Med Intensiva. 2020;67 doi: 10.1016/j.redar.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redar.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7474905</ArticleId><ArticleId IdType="pubmed">33023765</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C., Levy J.H., Ageno W., Connors J.M., Hunt B.J., Iba T., et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1859&#x2013;1865. doi: 10.1111/jth.14929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14929</ArticleId><ArticleId IdType="pmc">PMC7283841</ArticleId><ArticleId IdType="pubmed">32459046</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett C.D., Moore H.B., Yaffe M.B., Moore E.E. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment. Journal of Thrombosis and Haemostasis. 2020;18:2060&#x2013;2063. doi: 10.1111/jth.14860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14860</ArticleId><ArticleId IdType="pmc">PMC9770921</ArticleId><ArticleId IdType="pubmed">32302462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:2950&#x2013;2973. doi: 10.1016/j.jacc.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>ACTIV N Trial of blood thinners pauses enrollment of critically ill COVID-19 patients. NIH News Release. 2021</Citation></Reference><Reference><Citation>Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients. NHLBI News Statement.</Citation></Reference><Reference><Citation>Cuker A., Tseng E.K., Nieuwlaat R., Angchaisuksiri P., Blair C., Dane K., et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5:872&#x2013;888. doi: 10.1182/bloodadvances.2020003763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003763</ArticleId><ArticleId IdType="pmc">PMC7869684</ArticleId><ArticleId IdType="pubmed">33560401</ArticleId></ArticleIdList></Reference><Reference><Citation>Health. NI of. COVID-19 Treatment Guidelines Panel Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021 [Accessed 3 April 2021]. https://www.covid19treatmentguidelines.nih.gov/ Available in:</Citation></Reference><Reference><Citation>Jim&#xe9;nez D., Garc&#xed;a-Sanchez A., Rali P., Muriel A., Bikdeli B., Ruiz-Artacho P., et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 A Systematic Review and Meta-analysis. Chest. 2021;159:1182&#x2013;1196. doi: 10.1016/j.chest.2020.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7670889</ArticleId><ArticleId IdType="pubmed">33217420</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni G.N., Lala A., Bagiella E., Chang H.L., Moreno P.R., Pujadas E., et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVOD-19. J Am Coll Cardiol. 2020;76:1815&#x2013;1826. doi: 10.1016/j.jacc.2020.08.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.08.041</ArticleId><ArticleId IdType="pmc">PMC7449655</ArticleId><ArticleId IdType="pubmed">32860872</ArticleId></ArticleIdList></Reference><Reference><Citation>Godier A., Clausse D., Meslin S., Bazine M., Lang E., Huche F., et al. Major bleeding complications in critically ill patients with COVID-19 pneumonia. J Thromb Thrombolysis. 2021:3&#x2013;6. doi: 10.1007/s11239-021-02403-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02403-9</ArticleId><ArticleId IdType="pmc">PMC7919235</ArticleId><ArticleId IdType="pubmed">33646501</ArticleId></ArticleIdList></Reference><Reference><Citation>Llitjos J.F., Leclerc M., Chochois C., Monsallier J.M., Ramakers M., Auvray M., et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18:1743&#x2013;1746. doi: 10.1111/jth.14869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14869</ArticleId><ArticleId IdType="pmc">PMC7264774</ArticleId><ArticleId IdType="pubmed">32320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahum J., Morichau-Beauchant T., Daviaud F., Echegut P., Fichet J., Maillet J.M., et al. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) JAMA Netw open. 2020;3 doi: 10.1001/jamanetworkopen.2020.10478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.10478</ArticleId><ArticleId IdType="pmc">PMC7260620</ArticleId><ArticleId IdType="pubmed">32469410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35037857</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1669-9106</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>1</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Medicina</Title><ISOAbbreviation>Medicina (B Aires)</ISOAbbreviation></Journal><ArticleTitle>[Thromboembolic complications in patients with COVID-19].</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>27</EndPage><MedlinePgn>21-27</MedlinePgn></Pagination><Abstract><AbstractText>Coronavirus disease-19 has emerged as a devastating global public health crisis. An increased frequency of arterial and venous thrombosis was observed in COVID-19 infection. The objective of this study was to describe the thromboembolic complications of patients hospitalized for COVID-19 and their evolution. A prospective single-center study was conducted that compared the characteristics, risk factors, thromboembolic event rate, hospital stay and mortality among patients admitted to intensive care or general ward. The mean age of population was 46 &#xb1; 18 years, and 52% were female. The global rate of thromboembolic events was 4.4%, significantly higher in intensive unit patients (29% vs 1.4%; p &lt; 0.001) despite the high use of prophylactic heparin (91.1% vs. 84.9%; p &lt; 0.1). The independent predictive factors for the development of thromboembolic events were: age, D-dimer and creatinine. Of the patients admitted to intensive care, 45.1% required mechanical ventilation. Overall mortality was 4.3%, significantly higher in intensive care patients than in the general hospital ward (29% vs. 1.3%; p &lt; 0.0001). Patients requiring hospitalization due to infection secondary to COVID-19 have a high rate of thromboembolic events despite the use of thromboprophylaxis with heparin, generating a negative prognostic impact on the survival of patients admitted to intensive care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lalor</LastName><ForeName>Nicol&#xe1;s</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Servicio Cardiolog&#xed;a, Sanatorio Anchorena, Buenos Aires, Argentina. E-mail: nicolaslalor@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raffaeli</LastName><ForeName>Alesis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio Cardiolog&#xed;a, Sanatorio Anchorena, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cl&#xed;nica M&#xe9;dica, Sanatorio Anchorena, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silveyra</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cl&#xed;nica M&#xe9;dica, Sanatorio Anchorena, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aphalo</LastName><ForeName>Vanina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Terapia Intensiva, Sanatorio Anchorena, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scapellato</LastName><ForeName>Jos&#xe9; L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Cl&#xed;nica M&#xe9;dica, Sanatorio Anchorena, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Complicaciones tromboemb&#xf3;licas de los pacientes internados por COVID-19.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Medicina (B Aires)</MedlineTA><NlmUniqueID>0204271</NlmUniqueID><ISSNLinking>0025-7680</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>La enfermedad producida por el COVID-19 ha generado un problema sanitario mundial sin precedentes. La infecci&#xf3;n se considera como un potencial factor de riesgo para desarrollar complicaciones tromboemb&#xf3;licas, principalmente, embolia pulmonar, infarto de miocardio y accidente cerebrovascular. El objetivo de este trabajo fue describirlas en los pacientes internados por COVID-19 y su evoluci&#xf3;n. Se realiz&#xf3; un estudio observacional unic&#xe9;ntrico prospectivo que compar&#xf3; las caracter&#xed;sticas basales, factores de riesgo, tasa de eventos tromboemb&#xf3;licos, estad&#xed;a y mortalidad hospitalaria entre los pacientes que se internaron en cuidados intensivos o sala general. Se incluyeron 1125 pacientes, 124 internados en unidad cuidados intensivos y 1001 internados en sala general de internaci&#xf3;n. La edad promedio fue de 46 &#xb1; 18 a&#xf1;os, con 585 (52%) de sexo femenino. La tasa global de eventos tromboemb&#xf3;licos fue de 4.4%, siendo significativamente mayor en los pacientes de UCI (29% vs. 1.4%; p &lt; 0.001) a pesar del elevado uso de heparina profil&#xe1;ctica (91.1% vs. 84.9%; p &lt; 0.1), comparados con los internados en SGI. Los factores predictores independientes de desarrollo de eventos tromboemb&#xf3;licos fueron: la edad, el d&#xed;mero D y la creatinina. La mortalidad global fue 4.3%, siendo significativamente mayor en los pacientes de cuidados intensivos sobre los de sala general de internaci&#xf3;n (29% vs. 1.3%; p &lt; 0.001). Los pacientes que requieren internaci&#xf3;n por COVID-19 presentan elevada tasa de eventos tromboemb&#xf3;licos a pesar del uso de tromboprofilaxis con heparina, generando un impacto pron&#xf3;stico negativo sobre la supervivencia de aquellos internados en cuidados intensivos.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anticoagulation</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>17</Day><Hour>12</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35037857</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32591185</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2341-1929</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Season>Aug-Sep</Season></PubDate></JournalIssue><Title>Revista espanola de anestesiologia y reanimacion</Title><ISOAbbreviation>Rev Esp Anestesiol Reanim (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection.</ArticleTitle><Pagination><StartPage>391</StartPage><EndPage>399</EndPage><MedlinePgn>391-399</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redar.2020.05.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0034-9356(20)30123-7</ELocationID><Abstract><AbstractText>The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Llau</LastName><ForeName>J V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a-Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor, Hospital Universitari Doctor Peset, SEDAR, Valencia, Espa&#xf1;a. Electronic address: juanvllau@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrandis</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a-Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor, Hospital Universitari i Polit&#xe8;cnic La Fe, SEDAR, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sierra</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a-Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor, Fundaci&#xf3; Puigvert, SEDAR , Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a-Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor, Cl&#xed;nica Universidad de Navarra, SEDAR, Pamplona, Navarra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassinello</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a-Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor, Hospital Universitario Miguel Servet, SEDAR, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Luque</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a-Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor, Hospital Universitario Virgen de la Victoria, SEDAR, M&#xe1;laga, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Universitario La Paz-Carlos III, SEMICYUC, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amezaga</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Universitario Son Espases, SEMICYUC, Palma de Mallorca, Baleares, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gero</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Universitario, SEMICYUC, Burgos, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Cl&#xed;nico Universitario, SEMICYUC, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Germans Trias i Pujol, SEMICYUC, Badalona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D017065">Practice Guideline</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Recomendaciones de consenso SEDAR-SEMICYUC sobre el manejo de las alteraciones de la hemostasia en los pacientes graves con infecci&#xf3;n por COVID-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Anestesiol Reanim (Engl Ed)</MedlineTA><NlmUniqueID>101778594</NlmUniqueID><ISSNLinking>2341-1929</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001778" MajorTopicYN="N">Blood Coagulation Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011250" MajorTopicYN="N">Pregnancy Complications, Hematologic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>La infecci&#xf3;n por el coronavirus SARS-CoV-2, causante de la enfermedad denominada COVID-19, provoca alteraciones fundamentalmente en el sistema respiratorio. En los pacientes graves, con frecuencia la enfermedad evoluciona a un s&#xed;ndrome de distr&#xe9;s respiratorio agudo que puede predisponer a los pacientes a un estado de hipercoagulabilidad, con trombosis tanto a nivel venoso como arterial. Esta predisposici&#xf3;n presenta una fisiopatolog&#xed;a multifactorial, relacionada tanto con la hipoxia como con el grave proceso inflamatorio ligado a esta patolog&#xed;a, adem&#xe1;s de los factores tromb&#xf3;ticos adicionales presentes en muchos de los pacientes. Ante la necesidad de optimizar el manejo de la hipercoagulabilidad, los grupos de trabajo de las Sociedades Cient&#xed;ficas de Anestesiolog&#xed;a-Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor (SEDAR) y de Medicina Intensiva, Cr&#xed;tica y de Unidades Coronarias (SEMICYUC), han desarrollado un consenso para establecer unas pautas de actuaci&#xf3;n frente a las alteraciones de la hemostasia observadas en los pacientes graves con infecci&#xf3;n por COVID-19. Estas recomendaciones incluyen la profilaxis de la enfermedad tromboemb&#xf3;lica venosa en pacientes graves y en el periparto, el manejo de los pacientes en tratamiento cr&#xf3;nico con f&#xe1;rmacos antiagregantes o anticoagulantes, de las complicaciones hemorr&#xe1;gicas en la evoluci&#xf3;n de la enfermedad y de la interpretaci&#xf3;n de las alteraciones generales de la hemostasia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-platelets</Keyword><Keyword MajorTopicYN="N">Anticoagulantes</Keyword><Keyword MajorTopicYN="N">Anticoagulants</Keyword><Keyword MajorTopicYN="N">Antitromb&#xf3;ticos</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Complicaciones del embarazo</Keyword><Keyword MajorTopicYN="N">Coronavirus infections</Keyword><Keyword MajorTopicYN="N">Heparina de bajo peso molecular</Keyword><Keyword MajorTopicYN="N">Infecciones por coronavirus</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Pregnancy complications</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword><Keyword MajorTopicYN="N">Trombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32591185</ArticleId><ArticleId IdType="pmc">PMC7402104</ArticleId><ArticleId IdType="doi">10.1016/j.redar.2020.05.007</ArticleId><ArticleId IdType="pii">S0034-9356(20)30123-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844&#x2013;847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Yang H., Liu R., Liu F., Wu K., Li J., et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 doi: 10.1515/cclm-2020-0188. (Online ahead of print)</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0188</ArticleId><ArticleId IdType="pubmed">32172226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., Jerome K.R., Nalla A.K., et al. Covid-19 in critically ill patients in the Seattle Region &#x2014; case series. N Engl J Med. 2020;382:2012&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7143164</ArticleId><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.G., Ni Z., Hu Y., Liang W., Ou C., He J., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YW, Schmitz JE, Persing DH, Stratton CW. The laboratory diagnosis of COVID-19 infection: current issues and challenges. Clin Microbiol. J Clin Microbiol 58:e00512&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269383</ArticleId><ArticleId IdType="pubmed">32245835</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan B.E., Chong V.C.L., Chan S.S.W., Lim G.H., Lim K.G.E., Tan G.B., et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95:E131&#x2013;E153.</Citation><ArticleIdList><ArticleId IdType="pubmed">32129508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Huang M., Li D., Tang N. Difference of coagulation features between severe pnaeumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thomb Thrombolysis. 2020 doi: 10.1007/s11239-020-02105-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02105-8</ArticleId><ArticleId IdType="pmc">PMC7124128</ArticleId><ArticleId IdType="pubmed">32246317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. JACC. 2020 S0735-1097(20)35008-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234 (May)):1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262324</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F., Kruip M., van der Meer N., Arbous M., Gommers D., Kant K., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W., Yu H., Gou J., Li X., Sun Y., Li J., Liu L., et al. Clinical pathology of critical patient with novel Coronavirus Pneumonia (COVID-19) Preprints. 2020 2020020407.</Citation></Reference><Reference><Citation>Iba T., Levy J.H., Raj A., Warkentin T.E. Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Clin Med. 2019;8:728. doi: 10.3390/jcm8050728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8050728</ArticleId><ArticleId IdType="pmc">PMC6572234</ArticleId><ArticleId IdType="pubmed">31121897</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Nisio M.D., Levy J.H., Kitamura N., Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623518</ArticleId><ArticleId IdType="pubmed">28963294</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F.B., Jr, Toh C.-H., Hoots W.K., Wada H., Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempfle C.E., Wurst M., Smolinski M., Lorenz S., Osika A., Olenik D., et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost. 2004;91:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">15045145</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R [Updated 20 March 2020]. Treasure Island (FL): StatPearls Publishing Features, evaluation and treatment coronavirus (COVID-19). StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen K.S., Sawheny E., Kinasewitz G.T. Anticoagulant modulation of inflammation in severe sepsis. World J Crit Care Med. 2015;4:105&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411562</ArticleId><ArticleId IdType="pubmed">25938026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. [Accessed 29 March 2020]. Available from: https://thrombosisuk.org/covid-19-thrombosis.php.</Citation></Reference><Reference><Citation>Xie Y., Wang X., Yang P., Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology: Cardiothoracic Imaging. 2020;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233431</ArticleId><ArticleId IdType="pubmed">33778561</ArticleId></ArticleIdList></Reference><Reference><Citation>Llitjos J.F., Leclrec M., Chochois C., Monsallier J.M., Ramakers M., Auvray M., et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020 doi: 10.1111/jth.14869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14869</ArticleId><ArticleId IdType="pmc">PMC7264774</ArticleId><ArticleId IdType="pubmed">32320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Levy J.H. Thromboinflamation and the hypercoagulability of COVID-19. J Thomb Haemost. 2020:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9770920</ArticleId><ArticleId IdType="pubmed">32302453</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillet F., Behr J., Calame P., Aubry S., Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology. 2020 doi: 10.1148/radiol.2020201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020201544</ArticleId><ArticleId IdType="pmc">PMC7233384</ArticleId><ArticleId IdType="pubmed">32324103</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(March (5)):1094&#x2013;1099. doi: 10.1111/jtg.14817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jtg.14817</ArticleId><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.M., Vandvik P.O. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 2 Suppl:e691S&#x2013;e736S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278054</ArticleId><ArticleId IdType="pubmed">22315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormesher L., Simcox L., Tower C., Greer I.A. Management of inherited thrombophilia in pregnancy. Womens Health (Lond) 2016;12:433&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373275</ArticleId><ArticleId IdType="pubmed">27638899</ArticleId></ArticleIdList></Reference><Reference><Citation>Croles F.N., Nasserinejad K., Duvekot J.J., Kruip M., Meijer J.H.A., Leebeek K.F.W.G. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and Bayesian meta-analysis. BMJ. 2017;359:j4452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657463</ArticleId><ArticleId IdType="pubmed">29074563</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Lin K. Management of pregnant women infected with COVID-19. Lancet Infect Dis. 2020;20(May):513&#x2013;514. doi: 10.1016/S1473-3099(20)30191-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30191-2</ArticleId><ArticleId IdType="pmc">PMC7156224</ArticleId><ArticleId IdType="pubmed">32220285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Yang H., Cao Y., Cheng W., Duan T., Fan C. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynecol Obstet. 2020;149:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9087756</ArticleId><ArticleId IdType="pubmed">32196655</ArticleId></ArticleIdList></Reference><Reference><Citation>Documento t&#xe9;cnico. Manejo de la mujer embarazada y el reci&#xe9;n nacido con COVID-19 [versi&#xf3;n de 17 Mar 2020] [Accessed 7 April 2020]. Available from: https://www.sedar.es/images/site/NOTICIAS/coronavirus/Documento_manejo_embarazo_recien_nacido.pdf.pdf.</Citation></Reference><Reference><Citation>Interactions with Experimental COVID-19 therapies [Accessed 29 March 2020]. Available from: www.covid19-druginteractions.org.</Citation></Reference><Reference><Citation>Vivas D., Rold&#xe1;n I., Ferrandis R., Mar&#xed;n F., Rold&#xe1;n V., Tello-Montoliu A., et al. Manejo perioperatorio y periprocedimiento del tratamiento antitromb&#xf3;tico: documento de consenso de SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT y AEU. Rev Esp Cardiol. 2018;71:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">29887180</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivas D., Rold&#xe1;n V., Esteve-Pastor M.E., Rold&#xe1;n I., Tello-Montoliu A., Ruiz-Nodar J.M., et al. Recomendaciones sobre el tratamiento antitromb&#xf3;tico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Espa&#xf1;ola de Cardiolog&#xed;a. Rev Esp Cardiol. 2020 doi: 10.1016/j.recesp.2020.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2020.04.006</ArticleId><ArticleId IdType="pmc">PMC7176384</ArticleId><ArticleId IdType="pubmed">32327870</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906133</ArticleId><ArticleId IdType="pubmed">32338827</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25959637</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1579-2013</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Enfermeria clinica</Title><ISOAbbreviation>Enferm Clin</ISOAbbreviation></Journal><ArticleTitle>[Complications associated to central venous catheters in hematology patients].</ArticleTitle><Pagination><StartPage>138</StartPage><EndPage>142</EndPage><MedlinePgn>138-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.enfcli.2015.03.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1130-8621(15)00021-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To discover the incidence of central venous catheters (tunnelled, subcutaneous and PICC) in patients with onco-hematological conditions, hospitalized in the Hematology or Transplantations of Hematopoietic Stem Cells Units, in two tertiary care hospitals.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">A cross-sectional, descriptive study form was developed in order to gather sociodemographic, clinical data as well as complications and follow-up of the care protocol. Each catheter was assigned a correlative identification number. Information was collected on 366 catheters: 185 in the University Hospital Ram&#xf3;n y Cajal (HURYC), 80 tunnelled, 40 subcutaneous venous access and 65 PICC, and 181 in the University Hospital Gregorio Mara&#xf1;&#xf3;n (HUGM), 101 tunnelled and 80 subcutaneous venous access.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Major complications in the tunnellized were infections (13.7% in HURYC vs. 6.8% in HUGM - p&lt;0.001) and occlusions (at least once in 3.8% vs. 21.8%). In subcutaneous venous access, infections were confirmed in 5% in HURYC vs. 1.2% in HUGM. There were occlusions at least once in 10% in HUGM and no other significant complications were detected. Regarding PICC, information was only collected in HURYC, where complications were phlebitis 10.8%, thrombosis 7.7%, confirmed or suspected infection 4.6%, occlusion at least once 7.7%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Differences between hospitals with regard to major complications, infection and occlusion may be related to different care protocol. We need to stress the high incidence of phlebitis and thrombosis in PICC catheters, compared with data of lower incidence of other papers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a-Gab&#xe1;s</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unidad de Trasplante de Progenitores Hematopoy&#xe9;ticos y Hospitalizaci&#xf3;n, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a. Electronic address: cggabas@salud.madrid.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo-Ayala</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Trasplante de Progenitores Hematopoy&#xe9;ticos y Hospitalizaci&#xf3;n, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinojo-Mar&#xed;n</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unidad de Trasplante de Progenitores Hematopoy&#xe9;ticos y Hospitalizaci&#xf3;n, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muriel-Abajo</LastName><ForeName>M &#xc1;ngeles</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Unidad de Trasplante de Progenitores Hematopoy&#xe9;ticos y Hospitalizaci&#xf3;n, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Guti&#xe9;rrez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Unidad de Trasplante de Progenitores Hematopoy&#xe9;ticos y Hospitalizaci&#xf3;n, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mena-Arenas</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Unidad de Trasplante de Progenitores Hematopoy&#xe9;ticos y Hospitalizaci&#xf3;n, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Gonzalo</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Investigaci&#xf3;n, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao-Lozano</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Salud Monterozas, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Men&#xe9;ndez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madro&#xf1;ero-Agreda</LastName><ForeName>M Antonia</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Investigaci&#xf3;n de apoyo, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Complicaciones asociadas al cat&#xe9;ter venoso central en pacientes hematol&#xf3;gicos.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Enferm Clin</MedlineTA><NlmUniqueID>101190915</NlmUniqueID><ISSNLinking>1130-8621</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062905" MajorTopicYN="N">Central Venous Catheters</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010689" MajorTopicYN="N">Phlebitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Catheters indwelling</Keyword><Keyword MajorTopicYN="N">Cat&#xe9;ter de permanencia</Keyword><Keyword MajorTopicYN="N">Hematology patient</Keyword><Keyword MajorTopicYN="N">Heparin</Keyword><Keyword MajorTopicYN="N">Heparina</Keyword><Keyword MajorTopicYN="N">Infecci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Paciente hematol&#xf3;gico</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword><Keyword MajorTopicYN="N">Trombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25959637</ArticleId><ArticleId IdType="doi">10.1016/j.enfcli.2015.03.003</ArticleId><ArticleId IdType="pii">S1130-8621(15)00021-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">6610369</PMID><DateCompleted><Year>1984</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-3170</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>1984</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Angiologia</Title><ISOAbbreviation>Angiologia</ISOAbbreviation></Journal><ArticleTitle>[Hemorrhagic complications of anticoagulants (heparin and dicoumarins) in the treatment of deep venous thrombosis. Report of 176 consecutive patients].</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>120</EndPage><MedlinePgn>118-20</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mor&#xe1;n</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Almaz&#xe1;n</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ingelmo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>G&#xf3;mez Alonso</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Complicaciones hemorr&#xe1;gicas de los anticoagulantes (heparina y dicumar&#xed;nicos) durante el tratamiento de las trombosis venosas profundas. Estudio de 176 pacientes consecutivos.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Angiologia</MedlineTA><NlmUniqueID>0370545</NlmUniqueID><ISSNLinking>0003-3170</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003374">Coumarins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006417" MajorTopicYN="N">Hematuria</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012002" MajorTopicYN="N">Rectal Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013924" MajorTopicYN="N">Thrombophlebitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6610369</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>